Additional cytogenetic abnormalities (ACA) are considered a high risk feature in chronic myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the setting of new tyrosine kinase inhibitors (TKIs) is less well understood. Patients with CML in CP with or without ACA at diagnosis treated with frontline TKIs in prospective clinical trials were analyzed for outcomes. Among 603 patients treated, 29 (5%) had ACA. Patients with ACA included 2 of 72 (2.8%) treated with imatinib 400 mg, 9 of 207 (4.3%) with imatinib 800 mg, 10 of 148 (6.7%) with dasatinib, 6 of 126 (4.7%) with nilotinib, and 2 of 50 (4%) with ponatinib. There was a significantly higher rate of complete cytogenetic response (CCyR) at 6 months in patients without ACA (P 5 .02). However cumulative CCyR and major molecular response (MMR) rates were not different. Similarly, MR4.0 and MR4.5 rates were similar for both groups; two CML-ACA patients maintained MR 4.5 for at least 2 years. At 5 years, ACA at diagnosis did not significantly impact transformation-free, failure-free, event-free, or overall survival expectations. Acknowledging small sample size estimates, response rates and survival outcomes were comparable in CP with ACA irrespective of whether chromosomal abnormalities were "major route" or other. The presence of ACA at diagnosis does not confer worse prognosis for patients with CML treated with TKI. Thus, the presence of ACA at diagnosis should not alter treatment strategies in these patients.
| I N TR ODU C TI ON
Additional clonal cytogenetic abnormalities (ACA), or cytogenetic clonal evolution (CE) as it is also referred to, are a window to underlying genomic instability and frequently herald an impending progression of disease. The appearance of these purely nonrandom events during the course of therapy portend an adverse prognosis and signal overt disease progression and inferior survival. The frequency of these additional cytogenetic abnormalities increases, across the disease spectrum, from 5-10% at diagnosis in early chronic phase (CP), to 30% and 80% in accelerated (AP) and blast (BP) phase, respectively. [1] [2] [3] Although the detection of ACAs have been associated with inferior outcomes in AP and BP, 4 data on their prognostic implications when present at the time of diagnosis in chronic phase in the context of tyrosine kinase inhibitor (TKI) therapy is still scanty.
Some studies evaluating the role of ACA at the time of diagnosis on patients treated with imatinib suggest a negative prognostic impact on molecular/cytogenetic response rates and overall survival, but data has been conflicting and far from unequivocal. [4] [5] [6] [7] This has partly to do with the fact that ACAs constitute a heterogeneous collection of karyotypic abnormalities, with widely varying prognostic impact. To this effect, ACAs are broadly classified into "major" and "minor" route Ahmad Alhuraiji and Prajwal Boddu contributed equally to this manuscript.
chromosomal abnormalities. 8, 9 The most common ACAs including trisomy 8, a second Ph chromosome, chromosome 17 [isochromosome (17)(q10)], 1der (22) , are considered "major route changes," and sporadic, infrequent aberrations such as trisomy 21, t(3;12) , t(4;6), t(2;16), and t(1;21) among others are designated as minor ACAs. 8, 9 It has been recently reported that during disease progression, major, and not minor, route abnormalities confer a negative prognosis. 10 In addition, individual, specific chromosomal abnormalities may also carry an adverse prognosis. For instance, chromosome 17, chromosome 3, and complex cytogenetic abnormalities have been associated with worse outcomes, while other abnormalities like deletion of derivative 9 have been shown to have no impact on prognosis when subjected to TKI therapy. [11] [12] [13] Thus, the minor route ACA are not an entirely homogenous group with certain changes such as those involving 11q23 and 3q26 associated with TKI resistance and inferior outcomes. 13, 14 Wang and colleagues proposed a new classification system accounting for the impact of these abnormalities. 15 The objective of this study was to analyze the impact of ACAs present at the time of diagnosis on outcome of patients with CML-CP receiving frontline TKI therapy. 
| M E TH ODS

| Study population
| Treatment monitoring
Routine karyotype with G-banding was performed in all patients at baseline and every 3 months for the first 12 months, and every 12 months thereafter with 20 evaluable metaphases required for determination of response. In instances where less than 20 metaphases were evaluable, cytogenetic response was scored by FISH.
Patients were also monitored by real-time PCR performed at baseline, every 3 months for the first 12 months, and every 6 months thereafter, or in case of suspected failure or disease progression. All BCR-ABL measures are reported in the international scale (IS).
| Definition of responses
Definition of responses were according to the ELN criteria. 16 times were compared with the log-rank test. Classification of CML-ACA patients by different classification (i.e., "major" vs "minor" route 10 changes, and "favorable" vs "poor" prognostic 15 groups) were based upon published criteria.
| RE S U L TS
A total of 603 consecutive patients were treated in the trials in question. Of the evaluated patients, 557 (92%) had at least 20 evaluable metaphases at diagnosis of whom 29 (5.2%) had ACA (4.8% of all patients treated). Detailed baseline characteristics of patients with and without ACA are outlined in Table 1 Among the 29 patients with ACA, major route abnormalities were identified in 12 patients (Supporting Information Table S1 ). These included trisomy 8, N 5 3; der (22) (Table 2) . Two patients with ACA have achieved a sustained MR4.5 (i.e., MR4.5 maintained for 2 years with at least 5 measurements); 78 of 574 (14%) patients without ACA had a sustained MR4.5 (P 5 .41). The median times to CHR, CCyR, and MMR in CP and CP-ACA patients were 0.8, 3, and 5.9 months, and 0.7, 3, and 5.3 months, respectively. There was a somewhat higher rate of CCyR at 6 months among patients with ACA but no other significant differences were noted. The long-term survival outcomes were similar between the two cohorts. There was a nonsignificant trend for an inferior failure-free (Supporting Information Figure S1 ) and overall survival 
| D ISC USSION
While inferior survival was more consistently associated with the presence of ACA at the time of diagnosis in CML patients treated with interferon alpha and other therapies, 17,18 the prognostic relevance of ACAs in CML-ACA patients treated with imatinib has been controversial. While some reports showed no prognostic significance of the presence of ACA on the response to frontline imatinib, 5, 6 other studies have suggested lower response rates and inferior overall survival for patients with ACA at the time of diagnosis. 4, 7 Some of this variability in reported outcomes may be related to the type of ACA present. Fabarius et al recently reported that patients with "major route" ACA, but not those with minor route abnormalities, had an inferior survival compared to those without ACA when treated with imatinib. 10 Such adverse prognostic impact of major route abnormalities is reflected in the 2013 ELN recommendations that include the presence of these abnormalities at diagnosis as a "warning" baseline sign that merits close attention. 16 It is important however to underscore that both "major"
and "minor" route abnormalities constitute heterogeneous entities With the use of TKI, the definitions of AP may need to be revised.
The presence of cytogenetic clonal evolution was established in 1988
by Kantarjian et al. 19 as one of the criteria defining accelerated phase disease. This definition was established based on a multivariate analysis that identified factors associated with a significantly inferior outcome.
This definition has remained standard for many years and is the same that has been used in all the major pivotal studies of TKI. The World Health Organization has proposed an alternative definition that has not been validated with prospective large trials using TKI. Our group reported the limited clinical context of the new proposal. 6 However, one criterion that seemed to be validated was the presence of "cytogenetic clonal evolution" at the time of diagnosis. 6 In that analysis, patients with these criteria had the best overall outcome when treated with imatinib. More recently, it has been reported that patients with criteria for AP at the time of diagnosis had a favorable outcome mimicking that of patients with CP criteria when treated with TKI, particularly if using second generation agents. 20 This is much in contrast with the emergence of AP during the course of therapy, whether by hematologic or cytogenetic parameters, which is indeed associated with an inferior response to therapy and long-term survival endpoints. 21, 22 Thus, with more specific therapy, more biologically oriented criteria for AP should be established. In one such approach, the genetic profile of patients in different stages of the disease were investigated. Patients with clinical CP criteria who had developed resistance to TKI had a genetic signature that resembled that of patients with blast phase. 23 Although these results have not been validated, they suggest that in the era of TKI, molecular markers may be more informative indicators of disease stage than the clinical features we have used to date.
Although the proportion of patients achieving CCyR at 6 months was statistically lower in the ACA group as compared to the non-ACA, this transient disadvantage disappeared at 12 months. Cytogenetic testing is performed every 3 months and it is possible that some of the responders might have improved their response to CCyR soon after the 6 month testing, i.e., between the sixth and nine month period. In this context, the achievement of complete cytogenetic remission at 12 months, is a far more powerful predictor for sustained PFS and CCyR status on TKIs than the presence of clonal evolution at diagnosis. 24, 25 The lack of an impact of ACA on the 12 month CCyR rates suggest Here, it is noteworthy that our series with CML-ACA included 11
imatinib-treated patients, 9 of whom were treated with imatinib-800
and two with imatinib-400 mg. Our previous experience 4 reporting on ACA at diagnosis and its impact on survival had only evaluated CML-CP patients treated on imatinib 400 mg daily dose. The Luatti et al group, which also reported inferior outcomes in CML-CP-ACA patients treated with imatinib 400/800 mg, did not explore the effect of imatinib dosing on response rates. Studies suggest that higher doses of imatinib are able induce earlier and deeper cytogenetic and molecular responses compared with imatinib 400 mg daily. 27, 28 Notably, all 11
imatinib-treated CML-ACA patients in our study had swift responses, achieving a major cytogenetic response by their third month of cytogenetic evaluation. This is particularly relevant since achieving major cytogenetic response at 3 months has superior prognostic impact over the presence/absence of baseline cytogenetic evolution, on survival. 4 It still remains to be clarified if higher doses of imatinib would be more beneficial in CML-ACA, as compared to the standard 400 mg dose, by their ability to induce earlier responses thereby positively impacting survival outcomes.
In conclusion, the presence of clonal evolution per se does not signal worse prognosis at least in the chronic phase. The type of abnormality appears to have a minimal role on outcome, although the highest risk abnormalities (i.e., abnormalities in chromosomes 3 and i17q) are rarely if ever detected at diagnosis. In this context, it could be questioned whether cytogenetic evaluation at diagnosis carries value. For the purposes of establishing a baseline that may help assess ACA that may occur later in the disease as pre-existent of newly occurring, such assessment may still have some, albeit modest, value.
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